Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11744801 | 0.98 | LMNA (0.49) | LMNATDP1MAPTMAPK1KMT2A | |
| SCHEMBL10570188 | 0.88 | TSHR (0.52) | LMNATDP1MAPTMAPK1KMT2A | |
| SCHEMBL2773681 | 0.86 | MAPT (0.52) | LMNATDP1MAPTMAPK1KMT2A | |
| SCHEMBL9316272 | 0.85 | LMNA (0.51) | LMNATDP1MAPTMAPK1KMT2A | |
| SCHEMBL9316270 | 0.82 | LMNA (0.53) | LMNATDP1MAPTMAPK1KMT2A | |
| SCHEMBL11037946 | 0.82 | LMNA (0.53) | LMNATDP1MAPTMAPK1KMT2A | |
| SCHEMBL11744807 | 0.82 | LMNA (0.49) | LMNATDP1MAPTMAPK1KMT2A | |
| SCHEMBL15227043 | 0.82 | NPC1 (0.49) | TDP1MAPTKDM4EPOLBNPC1 | |
| SCHEMBL27755237 | 0.79 | LMNA (0.54) | LMNATDP1MAPTMAPK1KMT2A | |
| SCHEMBL7719434 | 0.78 | POLB (0.49) | LMNATDP1MAPTMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7184691-A | — | — | None | — | — | JP | disclosed |
| US-12546788-B2 | Methods for differentiating destructive thyroiditis from other pathological conditions | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2026-02-10 | — | — | US | disclosed |
| US-20230168257-A1 | METHODS FOR DIFFERENTIATING DESTRUCTIVE THYROIDITIS FROM OTHER PATHOLOGICAL CONDITIONS | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2023-06-01 | — | — | US | disclosed |
| EP-4130746-A1 | METHOD FOR DIFFERENTIATING DESTRUCTIVE THYROIDITIS FROM OTHER PATHOLOGICAL CONDITIONS | ASKA Pharmaceutical Co., Ltd. (JP) | 2023-02-08 | — | — | EP | disclosed |
| CN-115398237-A | Method for distinguishing destructive thyroiditis from other pathological states | ASKA制药株式会社 | 2022-11-25 | — | — | CN | disclosed |
| CN-110317212-B | Synthesis of polycyclic carbamoylpyridone compounds | 吉利德科学公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-114394983-A | Synthesis of polycyclic carbamoylpyridone compounds | 吉利德科学公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-1549759-B1 | BACTERIAL TEST METHOD BY GLYCATED INTRACELLULAR ENZYMES | SIEMENS HEALTHCARE DIAGNOSTICS (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20080050762-A1 | METHODS AND COMPOSITIONS FOR COUPLED LUMINESCENT ASSAYS | COREY MICHAEL J | 2008-02-28 | — | — | US | disclosed |
| EP-1549759-A4 | BACTERIAL TEST METHOD BY GLYCATED LABEL BINDING | BAYER HEALTHCARE LLC (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060141546-A1 | Bacterial test method by glycated label binding | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 2006-06-29 | — | — | US | disclosed |
| EP-1549759-A1 | BACTERIAL TEST METHOD BY GLYCATED LABEL BINDING | Bayer Healthcare LLC (US) | 2005-07-06 | — | — | EP | disclosed |
| US-6811990-B1 | RAPID/FLEXIBLE MEASUREMENT OF CELL CYTOTOXICITY AND/OR PROLIFERATION; ENZYMATIC ACTIVITY COUPLED TO PRODUCTION OF HIGH-ENERGY MOLECULE (ATP) WHICH SERVES AS A SUBSTRATE FOR ILLUMINATION BY A LUCIFERASE; PHOSPHATASES | Corey, Michael J. | 2004-11-02 | — | — | US | disclosed |
| WO-2003106699-A1 | BACTERIAL TEST METHOD BY GLYCATED LABEL BINDING | BAYER HEALTHCARE LLC (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030232401-A1 | Bacterial test method by glycated label binding | BAYER CORPORATION | 2003-12-18 | — | — | US | disclosed |
| JP-H07184691-A | METHOD FOR MEASURING ACTIVITY OF PHOSPHATE BY CHEMILUMINESCENCE | TEIKOKU HORMONE MFG CO LTD | 1995-07-25 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12546788-B2 | Methods for differentiating destructive thyroiditis from other pathological conditions | TPO, TSHR, TH | LMNA 4267/4885TDP1 1285/4885MAPT 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.